investing

Why You Should Be Wary of Small-Cap Stocks

Small caps are ripe for a selloff. Tread carefully, especially in biotech companies.

Stocks of small companies have defied gravity for years now. From the bottom of the bear market on March 9, 2009, through February 14, the Russell 2000 index of small-capitalization stocks has returned an annualized 29.5%, trouncing the large-company-oriented Standard & Poor’s 500-stock index by an average of 4.4 percentage points per year.

See More: The Kip 25 Funds That Worry Us

What’s more, the Russell 2000 has beaten the S&P 500 every year since 1999, except for 2005, 2007 and 2011. Over that stretch it has returned an annualized 8.2%, compared with 4.7% for the S&P. That’s the longest run of market-beating returns for small caps ever—far eclipsing the old record set from 1973 to 1983.

But that huge outperformance has made small caps “extremely overvalued” in the view of Steven DeSanctis, small-cap strategist at Bank of America Merrill Lynch. “This is the upper bound of absolute valuation,” he says.(Biotech looks even more problematic; more on that in a minute.)

Small caps are about as expensive as they’ve ever been. Their price-earnings ratio—based on operating earnings over the past 12 months—is 23% greater than the P/E of the 300 largest U.S. companies, reports the Leuthold Group, a Minneapolis-based investment research firm. That premium is the second-highest since Leuthold began tracking the measure in 1983. (It was slightly higher in 2011).

Just look at the numbers. The 300 largest companies trade at a bit less than 16 times estimated 2014 earnings. In contrast, small caps--which Leuthold defines as stocks with a market value (share price times number of shares outstanding) of less than $3.3 billion-- trade at an average price-earnings ratio of just under 20.

What could spark a selloff? DeSanctis voices several concerns aside from valuation. First, the small-cap earnings reports in the fourth quarter were “sloppy,” he says. Year-over-year earnings growth has been a robust 12%, but more companies than usual have reported earnings below analysts’ estimates.

Second, he thinks the Federal Reserve’s tapering of its bond purchases will lead to greater volatility in the stock market. “The pickup in volatility is bad for small caps,” he says.

Third, DeSanctis says, analysts are wildly over-optimistic about earnings for the coming 12 months. On average, analysts predict that small-cap earnings will rise 20%, he says, but those forecasts are “very unrealistic.” He estimates 12% earnings growth. When companies report disappointing earnings, the market almost always punishes their stocks.

Fourth, bargains in small-cap land are scant, DeSanctis says. “Every stone has been overturned.” Only 10% of the stocks in the Russell 2000 sell for less than 10 times estimated earnings.

Companies in the Russell without earnings—which represented 12% of the index’s market value—led the index last year, an event DeSanctis calls “awfully strange.” Anytime speculative stocks lead the market, you should be concerned. Just a bit more than one-third of the firms with no profits were in health care, mainly biotechnology.

Small-cap biotech stocks have soared 72% from the start of 2013 through February 17. Many, if not most, of these companies expect to remain unprofitable for years to come, are looking for more financing and have just one or two compounds in the early stages of testing. Most such compounds never even get close to being approved for sale. and if they do get regulatory approval, the process can take years.

These biotech stocks trade at an average of 27 times revenues—that’s revenues, not earnings. That’s about 50% more than average. The only time they were more richly priced was just before the popping of the tech bubble in 2000.

The biotech industry may be approaching a turning point in drug development, and biotech companies are targeting major diseases, including cancer, dementia and heart disease. But as we learned during the tech meltdown, even if you invest in a company that is changing the world, you stand a good chance of losing money if you pay an insanely high price for its stock.

Steve Goldberg is an investment adviser in the Washington, D.C., area.

Most Popular

Your Guide to Roth Conversions
Special Report
Tax Breaks

Your Guide to Roth Conversions

A Kiplinger Special Report
February 25, 2021
The 25 Cheapest U.S. Cities to Live In
places to live

The 25 Cheapest U.S. Cities to Live In

Take a look at our list of American cities with the lowest costs of living. Is one of the cheapest cities in the U.S. right for you?
October 13, 2021
Gen X: How to Make Sure Your Future Self Remains Funded
personal finance

Gen X: How to Make Sure Your Future Self Remains Funded

If you’re a Gen Xer, like me, now might be the right time to talk to a financial professional to learn more about how to adjust your retirement planni…
October 20, 2021

Recommended

Invesco S&P 500 Equal Weight Financials Rides the Recovery
Kip ETF 20

Invesco S&P 500 Equal Weight Financials Rides the Recovery

Some of the fund's best-performing stocks over the past year were regional banks with market values below $30 billion.
October 28, 2021
The Pros and Cons of Target Date Funds with Tony Drake
Financial Planning

The Pros and Cons of Target Date Funds with Tony Drake

The simplicity of target date funds has made them popular, particularly among 401(k) savers. But investors may be paying a price.
October 19, 2021
Robo-Advisers: Weighing the Worth of Automated Advice
investing

Robo-Advisers: Weighing the Worth of Automated Advice

Some people do just fine with bare-bones advice that’s essentially generated by an algorithm. Until your financial life gets more complicated, you mig…
October 17, 2021
Yogi Berra Quotes Investors Can Live By
investing

Yogi Berra Quotes Investors Can Live By

Baseball legend Yogi Berra was wise, in his own muddled way, about more than just sports. His words hold truth in life – and in investing. Here are th…
October 13, 2021